Onyx Pharmaceuticals Inc.’s experimental cancer drug carfilzomib will get a standard review from U.S. regulators, instead of an accelerated process sought by the company. The Food and Drug Administration said the South San Francisco, California-based company hadn’t conducted the clinical trials necessary for the quicker review of carfilzomib, Onyx said today in a statement. The FDA scheduled a target date of July 27, four months later than under an accelerated approval, to decide whether to approve carfilzomib for patents with multiple myeloma, a cancer of plasma cells, Onyx said in its statement. The company, which developed Nexavar for kidney cancer, submitted its application in September.
